155 related articles for article (PubMed ID: 21920751)
1. Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
Mowbray CE; Bell AS; Clarke NP; Collins M; Jones RM; Lane CA; Liu WL; Newman SD; Paradowski M; Schenck EJ; Selby MD; Swain NA; Williams DH
Bioorg Med Chem Lett; 2011 Nov; 21(21):6596-602. PubMed ID: 21920751
[TBL] [Abstract][Full Text] [Related]
2. A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787.
Andaloussi M; Lim HD; van der Meer T; Sijm M; Poulie CB; de Esch IJ; Leurs R; Smits RA
Bioorg Med Chem Lett; 2013 May; 23(9):2663-70. PubMed ID: 23558237
[TBL] [Abstract][Full Text] [Related]
3. A new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic.
Engelhardt H; Smits RA; Leurs R; Haaksma E; de Esch IJ
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):628-43. PubMed ID: 19736622
[TBL] [Abstract][Full Text] [Related]
4. The effect of pK(a) on pyrimidine/pyridine-derived histamine H4 ligands.
Savall BM; Meduna SP; Venable J; Wei J; Smith RC; Hack MD; Thurmond RL; McGovern P; Edwards JP
Bioorg Med Chem Lett; 2014 Dec; 24(23):5489-92. PubMed ID: 25455490
[TBL] [Abstract][Full Text] [Related]
5. Major advances in the development of histamine H4 receptor ligands.
Smits RA; Leurs R; de Esch IJ
Drug Discov Today; 2009 Aug; 14(15-16):745-53. PubMed ID: 19477292
[TBL] [Abstract][Full Text] [Related]
6. Lead identification and optimization of diaminopyrimidines as histamine H4 receptor ligands.
Sander K; Kottke T; Proschak E; Tanrikulu Y; Schneider EH; Seifert R; Schneider G; Stark H
Inflamm Res; 2010 Mar; 59 Suppl 2():S249-51. PubMed ID: 20012148
[TBL] [Abstract][Full Text] [Related]
7. Piperazine modification in 2,4,6-triaminopyrimidine derivatives as histamine H4 receptor ligands.
Schreeb A; Walter M; Odadzic D; Schwed JS; Weizel L; Stark H
Pharmazie; 2013 Jul; 68(7):521-5. PubMed ID: 23923631
[TBL] [Abstract][Full Text] [Related]
8. Novel histamine H4 receptor ligands and their potential therapeutic applications: an update.
Kiss R; Keseru GM
Expert Opin Ther Pat; 2014 Nov; 24(11):1185-97. PubMed ID: 25219452
[TBL] [Abstract][Full Text] [Related]
9. 2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.
Hammer SG; Gobleder S; Naporra F; Wittmann HJ; Elz S; Heinrich MR; Strasser A
Bioorg Med Chem Lett; 2016 Jan; 26(2):292-300. PubMed ID: 26718844
[TBL] [Abstract][Full Text] [Related]
10. Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.
Savall BM; Edwards JP; Venable JD; Buzard DJ; Thurmond R; Hack M; McGovern P
Bioorg Med Chem Lett; 2010 Jun; 20(11):3367-71. PubMed ID: 20452213
[TBL] [Abstract][Full Text] [Related]
11. Histamine H4 receptor ligands and their potential therapeutic applications: an update.
Kiss R; Keserű GM
Expert Opin Ther Pat; 2012 Mar; 22(3):205-21. PubMed ID: 22385042
[TBL] [Abstract][Full Text] [Related]
12. Histamine H4 receptor ligands and their potential therapeutic applications.
Kiss R; Keseru GM
Expert Opin Ther Pat; 2009 Feb; 19(2):119-35. PubMed ID: 19441913
[TBL] [Abstract][Full Text] [Related]
13. Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H₄ receptor antagonists.
Savall BM; Chavez F; Tays K; Dunford PJ; Cowden JM; Hack MD; Wolin RL; Thurmond RL; Edwards JP
J Med Chem; 2014 Mar; 57(6):2429-39. PubMed ID: 24495018
[TBL] [Abstract][Full Text] [Related]
14. Histamine H3 and H4 receptors as novel drug targets.
Tiligada E; Zampeli E; Sander K; Stark H
Expert Opin Investig Drugs; 2009 Oct; 18(10):1519-31. PubMed ID: 19758107
[TBL] [Abstract][Full Text] [Related]
15. Is the H4 receptor a new drug target for allergies and asthma?
Salcedo C; Pontes C; Merlos M
Front Biosci (Elite Ed); 2013 Jan; 5(1):178-87. PubMed ID: 23276980
[TBL] [Abstract][Full Text] [Related]
16. Identification and hit-to-lead exploration of a novel series of histamine H4 receptor inverse agonists.
Cramp S; Dyke HJ; Higgs C; Clark DE; Gill M; Savy P; Jennings N; Price S; Lockey PM; Norman D; Porres S; Wilson F; Jones A; Ramsden N; Mangano R; Leggate D; Andersson M; Hale R
Bioorg Med Chem Lett; 2010 Apr; 20(8):2516-9. PubMed ID: 20299215
[TBL] [Abstract][Full Text] [Related]
17. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of astemizole-derived compounds at the histamine H1 and H4 receptor--H1/H4 receptor selectivity.
Wagner E; Wittmann HJ; Elz S; Strasser A
Naunyn Schmiedebergs Arch Pharmacol; 2014 Mar; 387(3):235-50. PubMed ID: 24241585
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of novel histamine H4 receptor antagonists.
Lane CA; Hay D; Mowbray CE; Paradowski M; Selby MD; Swain NA; Williams DH
Bioorg Med Chem Lett; 2012 Jan; 22(2):1156-9. PubMed ID: 22189138
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of a 2-benzothiazolylphenylmethyl ether class of histamine H4 receptor antagonists.
Labeeuw O; Levoin N; Billot X; Danvy D; Calmels T; Krief S; Ligneau X; Berrebi-Bertrand I; Robert P; Lecomte JM; Schwartz JC; Capet M
Bioorg Med Chem Lett; 2016 Nov; 26(21):5263-5266. PubMed ID: 27692832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
